Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The LincRNA HOTAIRM1 , Located in the HOXA genomic Region , impacts Prognosis in Acute Myeloid Leukemia and Is Associated with a Distinctive microRNA Signature

Marina Díaz-Beyá, MD PhD, Alfons Navarro, PhD, Salut Brunet, MD PhD, Josep F Nomdedeu, MD, Anna Cordeiro, Msc, Marta Pratcorona, MD PhD, Meritxell Nomdedeu, MD PhD, Ruth M Risueño, PhD, Josep-Maria Ribera, MD PhD, Mar Tormo, MDPhD, Rafael F. Duarte, MD PhD, Olga Salamero, MD, Lourdes Escoda, MD, David Gallardo, MD PhD, Carmen Pedro, MD, Josep M Marti-Tutusaus, Jorge Sierra, MD, Mariano Monzó, MD PhD, Jordi Esteve, MD PhD

Blood (2014) 124 (21): 1003.

https://doi.org/10.1182/blood.V124.21.1003.1003

Published: 2014

Journal Articles

Prognostic Impact of the Levels of Expression of Cell Surface Proteins Commonly Expressed by Blasts and Hematopoietic Precursor Cells in De Novo AML Patients: A Report From the Spanish Cetlam Study Group

Blood (2012) 120 (21): 1452.

https://doi.org/10.1182/blood.V120.21.1452.1452

Published: 2012

Journal Articles

WT1 Levels At Diagnosis and POST-Induction Provide Prognostic Information in Adult De Novo AML. Results From the Spanish Cetlam Group.

Josep F Nomdedeu, MD, Montserrat Hoyos, Maite Carricondo, Elena Bussaglia, PhD, Camino Estivill, Jordi Esteve, MD, PhD, Mar Tormo, Rafael F Duarte, MD, PhD, Olga Salamero, MD, PAZ Queipo De Llano, MD, Joan Bargay, Inmaculada Heras, Josep M Marti-Tutusaus, Andreu Llorente, Josep-Maria Ribera, MD, PhD, David Gallardo, MD, PhD, Anna Aventin, MD, Salut Brunet, Jorge Sierra, MD

Blood (2012) 120 (21): 2524.

https://doi.org/10.1182/blood.V120.21.2524.2524

Published: 2012

Journal Articles

Feasibility of the AMLprofiler™ (Skyline array) in Patient Risk-Stratification in a Multicenter Trial. Comparison with the Standard Approach

Josep F Nomdedeu, MD, Eulalia Puigdecanet, Elena Bussaglia, PhD, Juan J Hernandez, Maite Carricondo, Camino Estivill, Josep M Marti-Tutusaus, Mar Tormo, Lurdes Zamora, PhD, Josep-Maria Ribera, MD, PhD, Lara Nonell, Anna Aventin, MD, Francesc Sole, Salut Brunet, Jorge Sierra, MD

Blood (2012) 120 (21): 4813.

https://doi.org/10.1182/blood.V120.21.4813.4813

Published: 2012

Journal Articles

Treatment for Primary Acute Myeloid Leukemia: Results of Two Consecutive Trials From the Spanish CETLAM Group Showing Improvement with the Use of G-CSF Priming and Precise Risk-Adapted Therapy.

Blood (2010) 116 (21): 1066.

https://doi.org/10.1182/blood.V116.21.1066.1066

Published: 2010

NARROW

The LincRNA HOTAIRM1 , Located in the HOXA genomic Region , impacts Prognosis in Acute Myeloid Leukemia and Is Associated with a Distinctive microRNA Signature

Prognostic Impact of the Levels of Expression of Cell Surface Proteins Commonly Expressed by Blasts and Hematopoietic Precursor Cells in De Novo AML Patients: A Report From the Spanish Cetlam Study Group

WT1 Levels At Diagnosis and POST-Induction Provide Prognostic Information in Adult De Novo AML. Results From the Spanish Cetlam Group.

Feasibility of the AMLprofiler™ (Skyline array) in Patient Risk-Stratification in a Multicenter Trial. Comparison with the Standard Approach

Treatment for Primary Acute Myeloid Leukemia: Results of Two Consecutive Trials From the Spanish CETLAM Group Showing Improvement with the Use of G-CSF Priming and Precise Risk-Adapted Therapy.

Email alerts

ASH Publications

American Society of Hematology

The LincRNA HOTAIRM1 , Located in the HOXA genomic Region , impacts Prognosis in Acute Myeloid Leukemia and Is Associated with a Distinctive microRNA Signature

Prognostic Impact of the Levels of Expression of Cell Surface Proteins Commonly Expressed by Blasts and Hematopoietic Precursor Cells in De Novo AML Patients: A Report From the Spanish Cetlam Study Group

WT1 Levels At Diagnosis and POST-Induction Provide Prognostic Information in Adult De Novo AML. Results From the Spanish Cetlam Group.

Feasibility of the AMLprofiler™ (Skyline array) in Patient Risk-Stratification in a Multicenter Trial. Comparison with the Standard Approach

Treatment for Primary Acute Myeloid Leukemia: Results of Two Consecutive Trials From the Spanish CETLAM Group Showing Improvement with the Use of G-CSF Priming and Precise Risk-Adapted Therapy.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only